
Longeveron (LGVN) Stock Forecast & Price Target
Longeveron (LGVN) Analyst Ratings
Bulls say
Longeveron Inc. holds a promising outlook due to its investigational product, Lomecel-B, which has shown a 60% probability of approval for Hypoplastic Left Heart Syndrome (HLHS) based on meaningful survival benefits observed in the ELPIS-I clinical trial. The company's ELPIS II trial has achieved over 90% enrollment, and a recent positive engagement with the FDA has confirmed its status as a pivotal program, potentially allowing for a Biological License Application (BLA) submission by the second half of 2026. Furthermore, the conservative approach of not modeling sales for Alzheimer's disease or aging-related applications means that successful outcomes in these areas could substantially enhance forecasts and create additional value for investors.
Bears say
Longeveron Inc is projected to face significant financial challenges, with forecasts indicating a net loss of $2.62 per share for 2024, exacerbated by a higher-than-expected weighted average share count. Additionally, the company is grappling with substantial risks regarding the success of its investigational product, Lomecel-B, particularly in clinical trials and potential regulatory approvals, which could impact its future revenue streams. The outlook for 2025 remains negative, with an anticipated net loss of $1.46 per share, reflecting continued operational and market challenges.
This aggregate rating is based on analysts' research of Longeveron and is not a guaranteed prediction by Public.com or investment advice.
Longeveron (LGVN) Analyst Forecast & Price Prediction
Start investing in Longeveron (LGVN)
Order type
Buy in
Order amount
Est. shares
0 shares